##gff-version 3
##sequence-region P16473 1 764
P16473	UniProtKB	Signal peptide	1	20	.	.	.	.	
P16473	UniProtKB	Chain	21	764	.	.	.	ID=PRO_0000012786;Note=Thyrotropin receptor	
P16473	UniProtKB	Topological domain	21	413	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Transmembrane	414	441	.	.	.	Note=Helical%3B Name%3D1;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Topological domain	442	450	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Transmembrane	451	473	.	.	.	Note=Helical%3B Name%3D2;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Topological domain	474	494	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Transmembrane	495	517	.	.	.	Note=Helical%3B Name%3D3;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Topological domain	518	537	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Transmembrane	538	560	.	.	.	Note=Helical%3B Name%3D4;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Topological domain	561	580	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Transmembrane	581	602	.	.	.	Note=Helical%3B Name%3D5;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Topological domain	603	625	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Transmembrane	626	649	.	.	.	Note=Helical%3B Name%3D6;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Topological domain	650	660	.	.	.	Note=Extracellular;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Transmembrane	661	682	.	.	.	Note=Helical%3B Name%3D7;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Topological domain	683	764	.	.	.	Note=Cytoplasmic;Ontology_term=ECO:0000255;evidence=ECO:0000255	
P16473	UniProtKB	Repeat	100	124	.	.	.	Note=LRR 1	
P16473	UniProtKB	Repeat	125	150	.	.	.	Note=LRR 2	
P16473	UniProtKB	Repeat	152	174	.	.	.	Note=LRR 3	
P16473	UniProtKB	Repeat	176	199	.	.	.	Note=LRR 4	
P16473	UniProtKB	Repeat	200	223	.	.	.	Note=LRR 5	
P16473	UniProtKB	Repeat	227	248	.	.	.	Note=LRR 6	
P16473	UniProtKB	Repeat	250	271	.	.	.	Note=LRR 7	
P16473	UniProtKB	Motif	762	764	.	.	.	Note=PDZ-binding	
P16473	UniProtKB	Modified residue	385	385	.	.	.	Note=Sulfotyrosine;Ontology_term=ECO:0000305;evidence=ECO:0000305|PubMed:11847099;Dbxref=PMID:11847099	
P16473	UniProtKB	Glycosylation	77	77	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11502179,ECO:0000269|PubMed:17542669;Dbxref=PMID:11502179,PMID:17542669	
P16473	UniProtKB	Glycosylation	99	99	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17542669;Dbxref=PMID:17542669	
P16473	UniProtKB	Glycosylation	113	113	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11502179,ECO:0000269|PubMed:17542669;Dbxref=PMID:11502179,PMID:17542669	
P16473	UniProtKB	Glycosylation	177	177	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17542669;Dbxref=PMID:17542669	
P16473	UniProtKB	Glycosylation	198	198	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11502179,ECO:0000269|PubMed:17542669;Dbxref=PMID:11502179,PMID:17542669	
P16473	UniProtKB	Glycosylation	302	302	.	.	.	Note=N-linked (GlcNAc...) asparagine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11502179;Dbxref=PMID:11502179	
P16473	UniProtKB	Disulfide bond	31	41	.	.	.	.	
P16473	UniProtKB	Disulfide bond	494	569	.	.	.	Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00521	
P16473	UniProtKB	Alternative sequence	232	274	.	.	.	ID=VSP_044643;Note=In isoform 3. DVSQTSVTALPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTR->VENVAVSGKGFCKSLFSWLYRLPLGRKSLSFETQKAPRSSMPS;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:15489334;Dbxref=PMID:15489334	
P16473	UniProtKB	Alternative sequence	232	253	.	.	.	ID=VSP_001981;Note=In isoform Short. DVSQTSVTALPSKGLEHLKELI->LPLGRKSLSFETQKAPRSSMPS;Ontology_term=ECO:0000303,ECO:0000303,ECO:0000303;evidence=ECO:0000303|PubMed:1445355,ECO:0000303|PubMed:1530609,ECO:0000303|PubMed:15489334;Dbxref=PMID:1445355,PMID:1530609,PMID:15489334	
P16473	UniProtKB	Alternative sequence	254	764	.	.	.	ID=VSP_001982;Note=In isoform Short. Missing;Ontology_term=ECO:0000303,ECO:0000303,ECO:0000303;evidence=ECO:0000303|PubMed:1445355,ECO:0000303|PubMed:1530609,ECO:0000303|PubMed:15489334;Dbxref=PMID:1445355,PMID:1530609,PMID:15489334	
P16473	UniProtKB	Alternative sequence	275	764	.	.	.	ID=VSP_044644;Note=In isoform 3. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:15489334;Dbxref=PMID:15489334	
P16473	UniProtKB	Natural variant	34	34	.	.	.	ID=VAR_055925;Note=E->K;Dbxref=dbSNP:rs45499704	
P16473	UniProtKB	Natural variant	36	36	.	.	.	ID=VAR_003564;Note=In a patient with Graves disease. D->H;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12788902,ECO:0000269|PubMed:12930595,ECO:0000269|PubMed:14759073,ECO:0000269|PubMed:1955520,ECO:0000269|PubMed:7556878;Dbxref=dbSNP:rs61747482,PMID:12788902,PMID:12930595,PMID:14759073,PMID:1955520,PMID:7556878	
P16473	UniProtKB	Natural variant	41	41	.	.	.	ID=VAR_011519;Note=In CHNG1. C->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12050212,ECO:0000269|PubMed:8954020;Dbxref=PMID:12050212,PMID:8954020	
P16473	UniProtKB	Natural variant	52	52	.	.	.	ID=VAR_003565;Note=Does not contribute to the genetic susceptibility to Graves disease. P->T;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10651846,ECO:0000269|PubMed:12788902,ECO:0000269|PubMed:12930595,ECO:0000269|PubMed:14759073,ECO:0000269|PubMed:7488864,ECO:0000269|PubMed:7508946,ECO:0000269|PubMed:7528344;Dbxref=dbSNP:rs2234919,PMID:10651846,PMID:12788902,PMID:12930595,PMID:14759073,PMID:7488864,PMID:7508946,PMID:7528344	
P16473	UniProtKB	Natural variant	109	109	.	.	.	ID=VAR_011520;Note=In CHNG1. R->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9100579;Dbxref=PMID:9100579	
P16473	UniProtKB	Natural variant	162	162	.	.	.	ID=VAR_011521;Note=In CHNG1. P->A;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12050212,ECO:0000269|PubMed:15531543,ECO:0000269|PubMed:25978107,ECO:0000269|PubMed:7528344,ECO:0000269|PubMed:8954020;Dbxref=dbSNP:rs121908863,PMID:12050212,PMID:15531543,PMID:25978107,PMID:7528344,PMID:8954020	
P16473	UniProtKB	Natural variant	167	167	.	.	.	ID=VAR_011522;Note=In CHNG1. I->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7528344;Dbxref=PMID:7528344	
P16473	UniProtKB	Natural variant	183	183	.	.	.	ID=VAR_003566;Note=In HTFG%3B enhances receptor response to chorionic gonadotropin. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9854118;Dbxref=PMID:9854118	
P16473	UniProtKB	Natural variant	197	197	.	.	.	ID=VAR_003567;Note=In papillary cancer. F->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7647578;Dbxref=PMID:7647578	
P16473	UniProtKB	Natural variant	219	219	.	.	.	ID=VAR_003568;Note=In papillary cancer. D->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7647578;Dbxref=PMID:7647578	
P16473	UniProtKB	Natural variant	252	252	.	.	.	ID=VAR_021495;Note=In CHNG1%3B displays a low expression at the cell surface and a reduced response to bovine TSH in terms of cAMP production. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15531543;Dbxref=PMID:15531543	
P16473	UniProtKB	Natural variant	281	281	.	.	.	ID=VAR_003569;Note=In hyperthyroidism%3B congenital%3B due to a toxic adenoma. S->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9294132;Dbxref=PMID:9294132	
P16473	UniProtKB	Natural variant	281	281	.	.	.	ID=VAR_003570;Note=In HTNA%3B gain of function%3B found in toxic thyroid nodules and hyperfunctioning thyroid adenomas. S->N;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10852462,ECO:0000269|PubMed:11127522,ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:9253356,ECO:0000269|PubMed:9589634;Dbxref=PMID:10852462,PMID:11127522,PMID:11434721,PMID:9253356,PMID:9589634	
P16473	UniProtKB	Natural variant	281	281	.	.	.	ID=VAR_011523;Note=In hyperthyroidism%3B associated with hyperfunctioning thyroid adenomas. S->T;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9253356;Dbxref=PMID:9253356	
P16473	UniProtKB	Natural variant	310	310	.	.	.	ID=VAR_011524;Note=In CHNG1. R->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11095460;Dbxref=PMID:11095460	
P16473	UniProtKB	Natural variant	390	390	.	.	.	ID=VAR_011525;Note=In CHNG1%3B persistent hypothyroidism and defective thyroid development%3B abolishes high affinity hormone binding. C->W;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:8954020,ECO:0000269|PubMed:9329388;Dbxref=PMID:8954020,PMID:9329388	
P16473	UniProtKB	Natural variant	410	410	.	.	.	ID=VAR_011526;Note=In CHNG1%3B lack of adenylate cyclase activation. D->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8954020;Dbxref=PMID:8954020	
P16473	UniProtKB	Natural variant	425	425	.	.	.	ID=VAR_021496;Note=Found in toxic thyroid nodules%3B 8 to 9 times higher levels of basal cAMP than wild-type TSHR and similar response to maximal TSH stimulation. S->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11434721;Dbxref=PMID:11434721	
P16473	UniProtKB	Natural variant	431	431	.	.	.	ID=VAR_011527;Note=In HTNA%3B gain of function%3B constitutive activation of the G(s)/adenylyl cyclase system. G->S;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11127522,ECO:0000269|PubMed:11549687;Dbxref=PMID:11127522,PMID:11549687	
P16473	UniProtKB	Natural variant	432	432	.	.	.	ID=VAR_075585;Note=In CHNG1%3B abolishes cell membrane location%3B abolishes adenylate cyclase-activating G-protein coupled receptor signaling pathway%3B abolishes phospholipase C-activating G-protein coupled receptor signaling pathway. N->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25978107;Dbxref=PMID:25978107	
P16473	UniProtKB	Natural variant	449	449	.	.	.	ID=VAR_075586;Note=In CHNG1%3B no effect on cell membrane location%3B upon TSH stimulation decreases more phospholipase C-activating G-protein coupled receptor signaling pathway than adenylate cyclase-activating G-protein coupled receptor signaling pathway. P->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:25978107;Dbxref=PMID:25978107	
P16473	UniProtKB	Natural variant	450	450	.	.	.	ID=VAR_011528;Note=In CHNG1. R->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11442002;Dbxref=PMID:11442002	
P16473	UniProtKB	Natural variant	453	453	.	.	.	ID=VAR_011529;Note=In HTNA%3B sporadic%3B found in toxic thyroid nodules and hyperfunctioning thyroid adenomas. M->T;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:12213664,ECO:0000269|PubMed:8964822,ECO:0000269|PubMed:9253356;Dbxref=PMID:11434721,PMID:12213664,PMID:8964822,PMID:9253356	
P16473	UniProtKB	Natural variant	463	463	.	.	.	ID=VAR_011530;Note=In HTNA%3B gain of function. M->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11201847;Dbxref=PMID:11201847	
P16473	UniProtKB	Natural variant	467	467	.	.	.	ID=VAR_017295;Note=In CHNG1. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12050212;Dbxref=PMID:12050212	
P16473	UniProtKB	Natural variant	477	477	.	.	.	ID=VAR_017296;Note=In CHNG1%3B severe hypothyroidism. T->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10720030;Dbxref=PMID:10720030	
P16473	UniProtKB	Natural variant	486	486	.	.	.	ID=VAR_011531;Note=In HTNA%3B found in thyroid toxic nodules and hyperfunctioning thyroid adenomas%3B also in hyperfunctioning follicular carcinoma. I->F;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10852462,ECO:0000269|PubMed:11128715,ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:9253356;Dbxref=PMID:10852462,PMID:11128715,PMID:11434721,PMID:9253356	
P16473	UniProtKB	Natural variant	486	486	.	.	.	ID=VAR_011532;Note=In HTNA%3B found in hyperfunctioning thyroid adenomas. I->M;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10852462,ECO:0000269|PubMed:12213664,ECO:0000269|PubMed:9253356;Dbxref=PMID:10852462,PMID:12213664,PMID:9253356	
P16473	UniProtKB	Natural variant	498	498	.	.	.	ID=VAR_011533;Note=In CHNG1. G->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11442002;Dbxref=PMID:11442002	
P16473	UniProtKB	Natural variant	505	505	.	.	.	ID=VAR_003571;Note=In HTNA%3B found in toxic thyroid nodules. S->N;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:15163335,ECO:0000269|PubMed:9360555;Dbxref=PMID:11434721,PMID:15163335,PMID:9360555	
P16473	UniProtKB	Natural variant	505	505	.	.	.	ID=VAR_011534;Note=In HTNA%3B gain of function. S->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8636266;Dbxref=PMID:8636266	
P16473	UniProtKB	Natural variant	509	509	.	.	.	ID=VAR_011535;Note=In HTNA%3B gain of function. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7920658;Dbxref=PMID:7920658	
P16473	UniProtKB	Natural variant	512	512	.	.	.	ID=VAR_021497;Note=Found in toxic thyroid nodules%3B 5 times higher levels of basal cAMP than wild-type TSHR and slightly less response to maximal TSH stimulation. L->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11434721;Dbxref=PMID:11434721	
P16473	UniProtKB	Natural variant	512	512	.	.	.	ID=VAR_011536;Note=In hyperthyroidism%3B associated with autonomously functioning thyroid nodules%3B 3.3-fold increase in basal cAMP level. L->R;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11022192,ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:12213664;Dbxref=PMID:11022192,PMID:11434721,PMID:12213664	
P16473	UniProtKB	Natural variant	525	525	.	.	.	ID=VAR_011537;Note=In CHNG1%3B impairs adenylate cyclase activation. F->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8954020;Dbxref=PMID:8954020	
P16473	UniProtKB	Natural variant	528	528	.	.	.	ID=VAR_003572;Note=R->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9589634;Dbxref=PMID:9589634	
P16473	UniProtKB	Natural variant	553	553	.	.	.	ID=VAR_011538;Note=In CHNG1%3B severe hypothyroidism. A->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:14725684,ECO:0000269|PubMed:9185526;Dbxref=PMID:14725684,PMID:9185526	
P16473	UniProtKB	Natural variant	568	568	.	.	.	ID=VAR_011539;Note=In HTNA%3B found in thyroid toxic nodules and hyperfunctioning thyroid adenomas. I->T;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11081252,ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:9253356;Dbxref=PMID:11081252,PMID:11434721,PMID:9253356	
P16473	UniProtKB	Natural variant	593	593	.	.	.	ID=VAR_021498;Note=In toxic thyroid adenoma%3B requires 2 nucleotide substitutions%3B somatic mutation%3B constitutively activates the cAMP cascade. A->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12589819;Dbxref=PMID:12589819	
P16473	UniProtKB	Natural variant	597	597	.	.	.	ID=VAR_021499;Note=In HTNA%3B 11-fold increase in specific constitutive activity associated with reduction in receptor protein expression. V->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11517004;Dbxref=PMID:11517004	
P16473	UniProtKB	Natural variant	597	597	.	.	.	ID=VAR_011540;Note=In hyperthyroidism%3B congenital with severe thyrotoxicosis. V->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10560955;Dbxref=PMID:10560955	
P16473	UniProtKB	Natural variant	600	600	.	.	.	ID=VAR_017297;Note=In CHNG1. C->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12050212;Dbxref=PMID:12050212	
P16473	UniProtKB	Natural variant	606	606	.	.	.	ID=VAR_011541;Note=I->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10487707;Dbxref=PMID:10487707	
P16473	UniProtKB	Natural variant	619	619	.	.	.	ID=VAR_003573;Note=In hyperthyroidism%3B found in toxic thyroid nodules%3B associated with hyperfunctioning thyroid adenomas. D->G;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:8413627,ECO:0000269|PubMed:9253356;Dbxref=PMID:11434721,PMID:8413627,PMID:9253356	
P16473	UniProtKB	Natural variant	623	623	.	.	.	ID=VAR_003574;Note=In hyperthyroidism%3B associated with hyperfunctioning thyroid adenomas%3B gain of function%3B requires 2 nucleotide substitutions. A->I;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:8413627,ECO:0000269|PubMed:9253356;Dbxref=PMID:8413627,PMID:9253356	
P16473	UniProtKB	Natural variant	623	623	.	.	.	ID=VAR_011542;Note=In hyperthyroidism%3B found in toxic thyroid nodules%3B associated with hyperfunctioning thyroid adenomas%3B gain of function. A->V;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:7989485;Dbxref=PMID:11434721,PMID:7989485	
P16473	UniProtKB	Natural variant	629	629	.	.	.	ID=VAR_003575;Note=In HTNA%3B also in hyperfunctioning thyroid adenomas and non-adenomatous nodules. L->F;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10852462,ECO:0000269|PubMed:9253356,ECO:0000269|PubMed:9398746;Dbxref=PMID:10852462,PMID:9253356,PMID:9398746	
P16473	UniProtKB	Natural variant	630	630	.	.	.	ID=VAR_011543;Note=In hyperthyroidism%3B associated with hyperfunctioning thyroid adenomas. I->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9253356;Dbxref=PMID:9253356	
P16473	UniProtKB	Natural variant	631	631	.	.	.	ID=VAR_011544;Note=In hyperthyroidism%3B associated with hyperfunctioning thyroid adenomas. F->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8045989;Dbxref=PMID:8045989	
P16473	UniProtKB	Natural variant	631	631	.	.	.	ID=VAR_011545;Note=In HTNA%3B gain of function%3B found in toxic thyroid nodules and hyperfunctioning thyroid adenomas. F->L;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:7800007,ECO:0000269|PubMed:9253356;Dbxref=PMID:11434721,PMID:7800007,PMID:9253356	
P16473	UniProtKB	Natural variant	632	632	.	.	.	ID=VAR_011546;Note=In HTNA%3B found in toxic thyroid nodules and hyperfunctioning non-adenomatous nodules. T->A;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10852462,ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:12213664;Dbxref=PMID:10852462,PMID:11434721,PMID:12213664	
P16473	UniProtKB	Natural variant	632	632	.	.	.	ID=VAR_011547;Note=In HTNA%3B gain of function%3B found in thyroid toxic nodules and hyperfunctioning thyroid adenomas. T->I;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10852462,ECO:0000269|PubMed:11127522,ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:7989485,ECO:0000269|PubMed:8045989,ECO:0000269|PubMed:9253356,ECO:0000269|PubMed:9349581;Dbxref=PMID:10852462,PMID:11127522,PMID:11434721,PMID:7989485,PMID:8045989,PMID:9253356,PMID:9349581	
P16473	UniProtKB	Natural variant	633	633	.	.	.	ID=VAR_011548;Note=In hyperthyroidism%3B associated with hyperfunctioning thyroid adenomas. D->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9253356;Dbxref=PMID:9253356	
P16473	UniProtKB	Natural variant	633	633	.	.	.	ID=VAR_011549;Note=In HTNA%3B found in thyroid toxic nodules and hyperfunctioning thyroid adenomas. D->E;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10852462,ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:8045989,ECO:0000269|PubMed:9253356;Dbxref=PMID:10852462,PMID:11434721,PMID:8045989,PMID:9253356	
P16473	UniProtKB	Natural variant	633	633	.	.	.	ID=VAR_011550;Note=In hyperthyroidism%3B found in toxic thyroid nodules%3B associated with hyperfunctioning thyroid adenomas%3B also in hyperfunctioning insular carcinoma%3B with severe thyrotoxicosis%3B gain of function. D->H;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:9062474,ECO:0000269|PubMed:9253356;Dbxref=dbSNP:rs28937584,PMID:11434721,PMID:9062474,PMID:9253356	
P16473	UniProtKB	Natural variant	633	633	.	.	.	ID=VAR_011551;Note=In hyperthyroidism%3B found in toxic thyroid nodules%3B associated with hyperfunctioning thyroid adenomas. D->Y;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11434721,ECO:0000269|PubMed:8045989,ECO:0000269|PubMed:9253356;Dbxref=PMID:11434721,PMID:8045989,PMID:9253356	
P16473	UniProtKB	Natural variant	639	639	.	.	.	ID=VAR_021500;Note=Found in toxic thyroid nodules. P->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11434721;Dbxref=PMID:11434721	
P16473	UniProtKB	Natural variant	639	639	.	.	.	ID=VAR_011552;Note=In HTNA%3B gain of function. P->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10199795;Dbxref=PMID:10199795	
P16473	UniProtKB	Natural variant	647	647	.	.	.	ID=VAR_011553;Note=In HTNA%3B found in non-adenomatous hyperfunctioning nodules. A->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10852462;Dbxref=PMID:10852462	
P16473	UniProtKB	Natural variant	650	650	.	.	.	ID=VAR_011554;Note=In HTNA%3B gain of function. N->Y;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8636266;Dbxref=PMID:8636266	
P16473	UniProtKB	Natural variant	656	656	.	.	.	ID=VAR_021501;Note=Found in toxic thyroid nodules. V->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11434721;Dbxref=PMID:11434721	
P16473	UniProtKB	Natural variant	658	661	.	.	.	ID=VAR_011555;Note=In hyperthyroidism%3B associated with hyperfunctioning thyroid adenomas. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9253356;Dbxref=PMID:9253356	
P16473	UniProtKB	Natural variant	670	670	.	.	.	ID=VAR_011556;Note=In HTNA%3B gain of function. N->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8636266;Dbxref=PMID:8636266	
P16473	UniProtKB	Natural variant	672	672	.	.	.	ID=VAR_011557;Note=In HTNA%3B gain of function. C->Y;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7920658;Dbxref=PMID:7920658	
P16473	UniProtKB	Natural variant	677	677	.	.	.	ID=VAR_011558;Note=In thyroid carcinoma%3B with thyrotoxicosis%3B gain of function. L->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10037070;Dbxref=PMID:10037070	
P16473	UniProtKB	Natural variant	703	703	.	.	.	ID=VAR_011559;Note=A->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10487707;Dbxref=PMID:10487707	
P16473	UniProtKB	Natural variant	715	715	.	.	.	ID=VAR_003576;Note=In papillary cancer. N->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7647578;Dbxref=PMID:7647578	
P16473	UniProtKB	Natural variant	720	720	.	.	.	ID=VAR_011560;Note=Q->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10487707;Dbxref=PMID:10487707	
P16473	UniProtKB	Natural variant	723	723	.	.	.	ID=VAR_003577;Note=In papillary cancer. K->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7647578;Dbxref=PMID:7647578	
P16473	UniProtKB	Natural variant	727	727	.	.	.	ID=VAR_003578;Note=May be a predisposing factor in toxic multinodular goiter pathogenesis%3B activation of the cAMP cascade does not differ from the wild-type. D->E;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10487707,ECO:0000269|PubMed:10946859,ECO:0000269|PubMed:12508121,ECO:0000269|PubMed:12589819,ECO:0000269|PubMed:12788902,ECO:0000269|PubMed:2302212,ECO:0000269|PubMed:7647578;Dbxref=dbSNP:rs1991517,PMID:10487707,PMID:10946859,PMID:12508121,PMID:12589819,PMID:12788902,PMID:2302212,PMID:7647578	
P16473	UniProtKB	Mutagenesis	283	283	.	.	.	Note=Abolishes cell surface expression. C->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11847099;Dbxref=PMID:11847099	
P16473	UniProtKB	Mutagenesis	385	387	.	.	.	Note=Inhibits intracellular cAMP accumulation. YDY->EDE;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11847099;Dbxref=PMID:11847099	
P16473	UniProtKB	Mutagenesis	385	387	.	.	.	Note=Abolishes sulfation. Inhibits intracellular cAMP accumulation. YDY->FDF;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11847099;Dbxref=PMID:11847099	
P16473	UniProtKB	Mutagenesis	385	385	.	.	.	Note=Reduces binding with thyrotropin. Inhibits intracellular cAMP accumulation. Y->E;Ontology_term=ECO:0000269,ECO:0000305;evidence=ECO:0000269|PubMed:11847099,ECO:0000305|PubMed:11847099;Dbxref=PMID:11847099,PMID:11847099	
P16473	UniProtKB	Mutagenesis	385	385	.	.	.	Note=Reduces sulfation. Reduces binding with thyrotropin. Inhibits intracellular cAMP accumulation. Y->F;Ontology_term=ECO:0000269,ECO:0000305;evidence=ECO:0000269|PubMed:11847099,ECO:0000305|PubMed:11847099;Dbxref=PMID:11847099,PMID:11847099	
P16473	UniProtKB	Mutagenesis	387	387	.	.	.	Note=No change in intracellular cAMP accumulation. Y->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11847099;Dbxref=PMID:11847099	
P16473	UniProtKB	Mutagenesis	387	387	.	.	.	Note=Reduces sulfation. No change in intracellular cAMP accumulation. Y->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11847099;Dbxref=PMID:11847099	
P16473	UniProtKB	Sequence conflict	87	87	.	.	.	Note=V->L;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	196	198	.	.	.	Note=AFN->DFF;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	257	257	.	.	.	Note=T->S;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	264	264	.	.	.	Note=P->A;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	306	308	.	.	.	Note=MQS->IET;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	528	528	.	.	.	Note=R->A;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	601	601	.	.	.	Note=Y->H;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	635	635	.	.	.	Note=I->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	645	645	.	.	.	Note=L->V;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	669	669	.	.	.	Note=L->I;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Sequence conflict	744	744	.	.	.	Note=N->K;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P16473	UniProtKB	Beta strand	26	28	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	30	33	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Turn	35	37	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:3G04	
P16473	UniProtKB	Beta strand	38	41	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	56	61	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	65	67	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Turn	69	74	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	80	84	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Turn	94	96	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	97	99	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	105	111	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	121	123	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	130	136	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	152	160	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Turn	169	174	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	175	183	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	190	192	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:3G04	
P16473	UniProtKB	Turn	194	199	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	201	206	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Turn	218	223	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	229	232	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
P16473	UniProtKB	Beta strand	250	253	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:2XWT	
